BEACONLIGHT CAPITAL, LLC - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 243 filers reported holding HAEMONETICS CORP in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.

Quarter-by-quarter ownership
BEACONLIGHT CAPITAL, LLC ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q1 2022$2,506,000
-48.3%
39,626
-42.3%
0.79%
-62.5%
Q3 2021$4,848,000
-21.4%
68,682
-25.8%
2.12%
-3.9%
Q2 2021$6,168,000
-64.5%
92,550
-40.8%
2.20%
-21.3%
Q1 2021$17,361,000
+2.2%
156,395
+9.4%
2.80%
-45.7%
Q4 2020$16,981,000
+109.2%
142,994
+53.7%
5.15%
+77.4%
Q3 2020$8,118,000
-4.6%
93,040
-2.1%
2.90%
+2.3%
Q2 2020$8,511,000
-61.8%
95,033
-57.5%
2.84%
-52.1%
Q1 2020$22,285,000
+315.6%
223,613
+142.2%
5.92%
+201.1%
Q4 2017$5,362,000
-7.5%
92,317
-28.6%
1.97%
-35.7%
Q3 2017$5,798,000129,2173.06%
Other shareholders
HAEMONETICS CORP shareholders Q1 2022
NameSharesValueWeighting ↓
Millrace Asset Group, Inc. 19,264$1,7262.13%
Parkman Healthcare Partners LLC 88,962$7,969,2161.46%
HEARTLAND ADVISORS INC 256,414$24,435,2741.37%
Riverwater Partners LLC 15,553$1,393,2381.27%
KINGDON CAPITAL MANAGEMENT, L.L.C. 111,100$9,952,3381.15%
Lisanti Capital Growth, LLC 78,425$7,025,3121.11%
Aristotle Capital Boston, LLC 311,666$27,919,0540.90%
ROYCE & ASSOCIATES LP 947,550$84,881,5290.86%
CHASE INVESTMENT COUNSEL CORP 18,770$1,6810.84%
Virtus Investment Advisers, Inc. 13,662$1,223,8420.83%
View complete list of HAEMONETICS CORP shareholders